To the best of my knowledge, convalescent plasma is not at a marketable therapeutic, so it should not draw too much money from the companies of other therapeutics.


Gilead has EUA and is still down.

Leronlimab works.

Big media picking it up. I believe Forbes is a bit more important than proactive investors.

Cytodyn will continue to push incessantly forward.